Prilosec patent litigation
This article was originally published in The Tan Sheet
Executive Summary
New York federal court upholds validity of AstraZeneca's two formulation patents and rules that three of four companies involved in Rx omeprazole patent litigation - Andrx, Dr. Reddy's and Genpharm - infringe those patents. However, Schwarz Pharma's product does not infringe, Judge Barbara Jones says in Oct. 11 ruling. Decision is not expected to impact AstraZeneca/P&G's eventual OTC sale of the proton pump inhibitor. OTC Prilosec would carry a claim for prevention of frequent heartburn - which differs from the approved Rx indication - and is expected to garner three-year Hatch/Waxman exclusivity. P&G anticipates FDA approval of the OTC switch in first quarter of 2003...
You may also be interested in...
Dr. Reddy’s Stakes Claim In U.S. OTC Market With Leiner Deal
Dr. Reddy's Laboratories' foothold in the U.S. OTC drug market appears ready for expansion after the firm signed an exclusive 15-year OTC product development and marketing agreement with Leiner Health Products
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.